Glycine Supplementation Improves Cognitive Performance in Mexican Older Adults

NCT07643675 | Completed

• 1 other identifier: HGDFF/DIR/CEI/232/2024
• Study Type: interventional
• Target: 59
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study was to evaluate the effects of daily glycine supplementation on metabolic health and cognitive performance in older adults. Over a period of six months, participants received 1,000 mg of glycine per day to determine if this amino acid could improve markers of insulin resistance, glucose metabolism, and cognitive functions such as memory and executive tasks. The research aimed to identify whether this nutritional intervention provides a safe and effective strategy to support healthy aging, focusing on the link between metabolic balance and brain health in the elderly population.

Conditions

Older Adults With Cognitive Decline; Aging; Insulin Resistance Syndrome

Keywords

Glycine; Older Adults; Cognitive Decline; Brain-Derived Neutrophic Factor (BDNF); Cognitive Ag-ing; Inflammation.

Outcome Measures

Primary Outcomes (1)

• Brain-Derived Neurotrophic Factor (BDNF) levels

  Evaluated the effects of glycine supplementation on cognitive performance, as meas-ured by the MMSE and MoCA scales, and its correlation with serum Brain-Derived Neurotrophic Factor (BDNF) levels in older adults.

  Baseline (T0), 3 months (T3) and 6 months (T6)

Study Arms (1)

Glycine group

EXPERIMENTAL

Participants received an oral daily dose of 1,000 mg of glycine for a duration of 6 months to evaluate metabolic and cognitive outcomes.

Dietary Supplement: Glycine

Interventions

Glycine DIETARY_SUPPLEMENT

Oral supplementation of glycine at a dose of 1,000 mg per day, administered daily over a 6-month period.

Glycine group

Eligibility Criteria

• Age: 60 Years - 80 Years
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Individuals across all nutritional statuses according to Body Mass Index (BMI), under-weight, normal weight, overweight, and obesity

You may not qualify if:

• Clinically relevant comorbidities (requiring patient hospitalization or a diagnosis of any infectious/contagious disease), consumption of polyphenol-based supplements or herbal blends within the two weeks prior to the study and mental incapacity, lack of willingness, or language barriers that prevent adequate understanding or co-operation

Sponsors & Collaborators

• Brenda Sarahí Beristain Lujano: lead
• Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado: collaborator
• National Polytechnic Institute, Mexico: collaborator

Study Sites (1)

Escuela Superior de Medicina

México, State of Mexico, 01710, Mexico

Location

MeSH Terms

Conditions

Metabolic Syndrome; Cognitive Dysfunction; Inflammation

Interventions

Glycine

Condition Hierarchy (Ancestors)

Insulin Resistance; Hyperinsulinism; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Cognition Disorders; Neurocognitive Disorders; Mental Disorders; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Amino Acids; Amino Acids, Peptides, and Proteins

Study Officials

• Brenda Sarahí BS Beristain Lujano, MSc

  Escuela Superior de Medicina IPN

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: SUPPORTIVE CARE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Principal Investigator and Doctoral Researcher

Model Details: Single-group, open-label study designed to evaluate longitudinal changes in metabolic and cognitive parameters from baseline (T0) to 6 months (T6) following daily glycine supplementation.

Study Record Dates

• First Submitted: June 8, 2026
• First Posted: June 11, 2026
• Study Start: December 1, 2024
• Primary Completion: June 1, 2025
• Study Completion: December 1, 2025
• Last Updated: June 11, 2026

Record last verified: 2026-06

Data Sharing

• IPD Sharing: Will not share

Locations

ME (1)